KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $425,000.

  • TherapeuticsMD's Change in Accured Expenses rose 199.30% to $425,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$182,000, marking a year-over-year increase of 95.57%. This contributed to the annual value of -$1.0 million for FY2024, which is 93.60% up from last year.
  • Latest data reveals that TherapeuticsMD reported Change in Accured Expenses of $425,000 as of Q3 2025, which was up 323.68% from -$190,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Change in Accured Expenses registered a high of $19.1 million during Q3 2022, and its lowest value of -$14.1 million during Q4 2022.
  • Its 3-year average for Change in Accured Expenses is -$1.5 million, with a median of -$413,000 in 2024.
  • In the last 5 years, TherapeuticsMD's Change in Accured Expenses surged by 3,282.27% in 2022 and then crashed by 331.82% in 2025.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Change in Accured Expenses stood at -$8.9 million in 2021, then tumbled by 58.77% to -$14.1 million in 2022, then spiked by 73.04% to -$3.8 million in 2023, then soared by 81.79% to -$691,000 in 2024, then surged by 199.30% to $425,000 in 2025.
  • Its last three reported values are $425,000 in Q3 2025, -$190,000 for Q2 2025, and $274,000 during Q1 2025.